Stefano Cairo’s scientific training started in 1995 at DIBIT-San Raffaele Scientific Institute in Milan, Italy. As an undergraduate student, Cairo investigated the pathways that transduce integrin receptor signal at the focal adhesions. After graduating, he worked in the Group of Dr. Alexandre Reymond at TIGEM, Milan, at the molecular characterization of a novel, independent regulatory network of the bHLHZ family of transcription factors. In parallel, he contributed to the discovery and characterization of a TRIM protein family. In 2000, he joined Dr. Germana Maroni’s Group at TIGEM in Naples, Italy, and attended a Ph.D. program. His project focused on the functional interaction between the TRIM protein PML and Myc, a transcription factor of the bHLHZ family. In November 2004, he joined Marie-Annick Buendia’s Group as Postdoctoral Fellow at the Pasteur Institute, Paris, France. The project aimed at the molecular characterization of hepatoblastoma (HB), a pediatric form of liver cancer, by combining genomewide approaches and functional studies. This work led to the identification of a subset of aggressive HBs characterized by activation of Myc signaling and to the discovery of a gene and micro-RNA expression-based signatures that can identify such tumors. Since December 2009, he joined the Research and Development (R&D) department of Xentech, a French biotech that develops human tumor-graft models to test reference as well as innovative anticancer therapies. As head of the department, he coordinates Xentech R&D projects, which are focused on two main axes: the identification of biomarkers predictive of tumor response to treatment and the enrichment of the xenograft collection for each tumor type to establish robust preclinical phase II-like cohorts. These tumor panels will improve understanding of tumor pharmacological response and hopefully help clinicians with the treatment choice.
Biography Updated on 7 February 2012